Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26880625 | 0.84 | CFD (0.32) | PDCD1LG2CD274 | |
| SCHEMBL30296580 | 0.84 | CFD (0.32) | PDCD1LG2CD274 | |
| SCHEMBL26092432 | 0.84 | CFD (0.32) | PDCD1LG2CD274 | |
| SCHEMBL24571288 | 0.84 | CFD (0.32) | PDCD1LG2CD274 | |
| SCHEMBL29073920 | 0.81 | — | — | |
| SCHEMBL26880652 | 0.81 | — | — | |
| SCHEMBL30296381 | 0.78 | — | — | |
| SCHEMBL30296568 | 0.73 | — | — | |
| SCHEMBL30296471 | 0.71 | HPGD (0.31) | — | |
| SCHEMBL30391265 | 0.71 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118451080-A | Tricyclic GPR65 modulators | 帕蒂奥斯治疗有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | PDCD1LG2 2666/4885CD274 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.